» Articles » PMID: 18004964

Optic Pathway Gliomas: a Review

Overview
Journal Neurosurg Focus
Specialty Neurosurgery
Date 2007 Nov 17
PMID 18004964
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Optic pathway gliomas represent approximately 3-5% of childhood intracranial tumors. They usually occur in children during the first decade of life and are seen in 11-30% of patients with neurofibromatosis Type 1 (NF1). Although these tumors are typically low-grade gliomas, the clinical course and natural history are highly variable, making treatment paradigms difficult. Overall, however, they are often indolent tumors that can be observed over time for progression without initial treatment, especially in patients with NF1. Chemotherapy is the first-line treatment for progressive tumors, and radiation therapy is reserved for patients with progressive disease who are older than 5-7 years. Surgery is reserved for large tumors causing mass effect or hydrocephalus and tumors confined to the orbit or unilateral optic nerve.

Citing Articles

Idiopathic Optic Nerve Glioma: A Case Report.

Kotecha M, Singh V, Chodvadiya S, Manade V, Kamdar G Cureus. 2025; 16(12):e76112.

PMID: 39835035 PMC: 11744336. DOI: 10.7759/cureus.76112.


Visual deterioration outcomes following optic pathway glioma treatment: a 12-year single institution retrospective study.

Zhou W, Niu J, Liao C, Ren S, Ou Y, Liu W J Neurooncol. 2024; 170(2):363-375.

PMID: 39167244 DOI: 10.1007/s11060-024-04802-3.


Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic-Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview.

Calandrelli R, DApolito G, Martucci M, Giordano C, Schiarelli C, Marziali G Cancers (Basel). 2024; 16(14).

PMID: 39061172 PMC: 11275213. DOI: 10.3390/cancers16142532.


Novel treatments in optic pathway gliomas.

Maheshwari A, Pakravan M, Charoenkijkajorn C, Beres S, Lee A Front Ophthalmol (Lausanne). 2024; 2:992673.

PMID: 38983553 PMC: 11182137. DOI: 10.3389/fopht.2022.992673.


The History of Nerve Growth Factor: From Molecule to Drug.

Gavioli E, Mantelli F, Cesta M, Sacchetti M, Allegretti M Biomolecules. 2024; 14(6).

PMID: 38927039 PMC: 11201509. DOI: 10.3390/biom14060635.